Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation.
Poorrezagholi
F
F
Urology Nephrology Research Center (UNRC), Labbafi Nejad Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran. Poorreza@hotmail.com
Einollahi
B
B
Firoozan
A
A
Nafar
M
M
Yadegari
H
H
Moghaddam
S M M H
SM
Simforoosh
N
N
Basiri
A
A
Farhangi
S
S
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012107:Research Design; D016037:Single-Blind Method
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab